Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pifenidone is Used to Reduce Radiation Lung Injury in Lung Cancer Patients Previously Treated With Immune Checkpoint Inhibitors: A Single-arm, Open-label, Phase II Study

NCT05801133 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT05801133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05801133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pifenidone is Used to Reduce Radiation Lung Injury in Lung Cancer Patients Previously Treated With Immune Checkpoint Inhibitors: A Single-arm, Open-label, Phase II Study
Lead sponsor
Hubei Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2023
Completion date
October 31, 2025
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer